148 related articles for article (PubMed ID: 25277206)
1. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
O'Brien S; Golubovskaya VM; Conroy J; Liu S; Wang D; Liu B; Cance WG
Oncotarget; 2014 Sep; 5(17):7945-59. PubMed ID: 25277206
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.
Golubovskaya V; O'Brien S; Ho B; Heffler M; Conroy J; Hu Q; Wang D; Liu S; Cance WG
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1613-31. PubMed ID: 25656374
[TBL] [Abstract][Full Text] [Related]
3. FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.
Heffler M; Golubovskaya VM; Conroy J; Liu S; Wang D; Cance WG; Dunn KB
Anticancer Agents Med Chem; 2013 May; 13(4):584-94. PubMed ID: 22934709
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Heffler M; Golubovskaya VM; Dunn KM; Cance W
Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
[TBL] [Abstract][Full Text] [Related]
7. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
[TBL] [Abstract][Full Text] [Related]
9. The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.
Huang G; Ho B; Conroy J; Liu S; Qiang H; Golubovskaya V
Anticancer Agents Med Chem; 2014 Jan; 14(1):9-17. PubMed ID: 23387973
[TBL] [Abstract][Full Text] [Related]
10. Focal Adhesion Kinase Inhibitor Inhibits the Oxidative Damage Induced by Central Venous Catheter via Abolishing Focal Adhesion Kinase-Protein Kinase B Pathway Activation.
Wang Y; Lin S; Jiang P; Song Y; Zhao Y; Zheng Y
Biomed Res Int; 2021; 2021():6685493. PubMed ID: 33748278
[TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Kanteti R; Mirzapoiazova T; Riehm JJ; Dhanasingh I; Mambetsariev B; Wang J; Kulkarni P; Kaushik G; Seshacharyulu P; Ponnusamy MP; Kindler HL; Nasser MW; Batra SK; Salgia R
Cancer Biol Ther; 2018 Apr; 19(4):316-327. PubMed ID: 29303405
[TBL] [Abstract][Full Text] [Related]
12. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
Golubovskaya VM; Figel S; Ho BT; Johnson CP; Yemma M; Huang G; Zheng M; Nyberg C; Magis A; Ostrov DA; Gelman IH; Cance WG
Carcinogenesis; 2012 May; 33(5):1004-13. PubMed ID: 22402131
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Anderson HJ; Galileo DS
Cell Oncol (Dordr); 2016 Jun; 39(3):229-42. PubMed ID: 26883759
[TBL] [Abstract][Full Text] [Related]
15. In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).
Golubovskaya V; Curtin L; Groman A; Sexton S; Cance WG
Arch Toxicol; 2015 Jul; 89(7):1095-101. PubMed ID: 24915938
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
[TBL] [Abstract][Full Text] [Related]
17. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract][Full Text] [Related]
18. Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Stafman LL; Williams AP; Marayati R; Aye JM; Markert HR; Garner EF; Quinn CH; Lallani SB; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Sci Rep; 2019 Sep; 9(1):13259. PubMed ID: 31519958
[TBL] [Abstract][Full Text] [Related]
19. FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.
Kessler BE; Sharma V; Zhou Q; Jing X; Pike LA; Kerege AA; Sams SB; Schweppe RE
Mol Cancer Res; 2016 Sep; 14(9):869-82. PubMed ID: 27259715
[TBL] [Abstract][Full Text] [Related]
20. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Shah NR; Tancioni I; Ward KK; Lawson C; Chen XL; Jean C; Sulzmaier FJ; Uryu S; Miller NL; Connolly DC; Schlaepfer DD
Gynecol Oncol; 2014 Jul; 134(1):104-11. PubMed ID: 24786638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
